dc.contributor.author |
Petersen, Maya |
|
dc.contributor.author |
Balzer, Laura |
|
dc.contributor.author |
Kwarsiima, Dalsone |
|
dc.contributor.author |
Sang, Norton |
|
dc.contributor.author |
Chamie, Gabriel |
|
dc.contributor.author |
Ayieko, James |
|
dc.contributor.author |
Kabami, Jane |
|
dc.contributor.author |
Owaraganise, Asiphas |
|
dc.contributor.author |
Liegler, Teri |
|
dc.contributor.author |
Mwangwa, Florence |
|
dc.contributor.author |
Kadede, Kevin |
|
dc.contributor.author |
Jain, Vivek |
|
dc.contributor.author |
Plenty, Albert |
|
dc.contributor.author |
Brown, Lillian |
|
dc.contributor.author |
Lavoy, Geoff |
|
dc.contributor.author |
Schwab, Joshua |
|
dc.contributor.author |
Black, Douglas |
|
dc.contributor.author |
van der Laan, Mark |
|
dc.contributor.author |
Bukusi, Elizabeth A. |
|
dc.contributor.author |
Cohen, Craig R. |
|
dc.contributor.author |
Clark, Tamara D. |
|
dc.contributor.author |
Charlebois, Edwin |
|
dc.contributor.author |
Kamya, Moses |
|
dc.contributor.author |
Havlir, Diane |
|
dc.date.accessioned |
2021-01-01T21:58:21Z |
|
dc.date.available |
2021-01-01T21:58:21Z |
|
dc.date.issued |
2017 |
|
dc.identifier.issn |
0098-7484 |
|
dc.identifier.uri |
http://combine.alvar.ug/handle/1/48277 |
|
dc.description.abstract |
IMPORTANCE Antiretroviral treatment (ART) is now recommended for all HIV-positive persons. UNAIDS has set global targets to diagnose 90% of HIV-positive individuals, treat 90% of diagnosed individuals with ART, and suppress viral replication among 90% of treated individuals, for a population-level target of 73% of all HIV-positive persons with HIV viral suppression. OBJECTIVE To describe changes in the proportions of HIV-positive individuals with HIV viral suppression, HIV-positive individuals who had received a diagnosis, diagnosed individuals treated with ART, and treated individuals with HIV viral suppression, following implementation of a community-based testing and treatment program in rural East Africa. DESIGN, SETTING, AND PARTICIPANTS Observational analysis based on interim data from 16 rural Kenyan (n = 6) and Ugandan (n = 10) intervention communities in the SEARCH Study, an ongoing cluster randomized trial. Community residents who were 15 years or older (N = 77 774) were followed up for 2 years (2013-2014 to 2015-2016). HIV serostatus and plasma HIV RNA level were measured annually at multidisease health campaigns followed by home-based testing for nonattendees. All HIV-positive individuals were offered ART using a streamlined delivery model designed to reduce structural barriers, improve patient-clinician relationships, and enhance patient knowledge and attitudes about HIV. MAIN OUTCOMES AND MEASURES Primary outcome was viral suppression (plasma HIV RNA <500 copies/mL) among all HIV-positive individuals, assessed at baseline and after 1 and 2 years. Secondary outcomes included HIV diagnosis, ART among previously diagnosed individuals, and viral suppression among those who had initiated ART. RESULTS Among 77 774 residents (male, 45.3%; age 15-24 years, 35.1%), baseline HIV prevalence was 10.3%(7108 of 69 283 residents). The proportion of HIV-positive individuals with HIV viral suppression at baseline was 44.7%(95% CI, 43.5%-45.9%; 3464 of 7745 residents) and after 2 years of intervention was 80.2%(95% CI, 79.1%-81.2%; 5666 of 7068 residents), an increase of 35.5 percentage points (95% CI, 34.4-36.6). After 2 years, 95.9% of HIV-positive individuals had been previously diagnosed (95% CI, 95.3%-96.5%; 6780 of 7068 residents); 93.4% of those previously diagnosed had received ART (95% CI, 92.8%-94.0%; 6334 of 6780 residents); and 89.5% of those treated had achieved HIV viral suppression (95% CI, 88.6%-90.3%; 5666 of 6334 residents). CONCLUSIONS AND RELEVANCE Among individuals with HIV in rural Kenya and Uganda, implementation of community-based testing and treatment was associated with an increased proportion of HIV-positive adults who achieved viral suppression, along with increased HIV diagnosis and initiation of antiretroviral therapy. In these communities, the UNAIDS population-level viral suppression target was exceeded within 2 years after program implementation. |
|
dc.description.sponsorship |
National Institute of Allergy and Infectious Diseases at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [UM1AI069502, U01AI099959, R01AI074345] |
|
dc.description.sponsorship |
US President's Emergency Plan for AIDS ReliefUnited States Agency for International Development (USAID) |
|
dc.description.sponsorship |
Office of the Global AIDS Coordinator |
|
dc.description.sponsorship |
Gilead Sciences (Truvada donation) |
|
dc.description.sponsorship |
Office of AIDS ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA |
|
dc.description.sponsorship |
University of California, San Francisco-Gladstone Institute of Virology and Immunology Center for Aids ResearchUniversity of California System [P30 AI027763] |
|
dc.description.sponsorship |
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI074345, R01AI074345, R01AI074345, R01AI074345, R01AI074345, UM1AI069502, R01AI074345, R01AI074345, UM1AI069502, R01AI074345, R01AI074345, R01AI074345] Funding Source: NIH RePORTER |
|
dc.description.sponsorship |
NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246, P30MH062246] Funding Source: NIH RePORTER |
|
dc.language |
English |
|
dc.publisher |
AMER MEDICAL ASSOC |
|
dc.relation.ispartof |
JAMA-Journal of the American Medical Association |
|
dc.title |
Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa |
|
dc.type |
Article |
|
dc.identifier.isi |
000402706100016 |
|
dc.identifier.doi |
10.1001/jama.2017.5705 |
|
dc.identifier.pmid |
28586888 |
|
dc.publisher.city |
CHICAGO |
|
dc.publisher.address |
330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA |
|
dc.identifier.eissn |
1538-3598 |
|
dc.identifier.volume |
317 |
|
dc.identifier.issue |
21 |
|
dc.identifier.spage |
2196 |
|
dc.identifier.epage |
2206 |
|
dc.subject.wc |
Medicine, General & Internal |
|
dc.subject.sc |
General & Internal Medicine |
|
dc.description.oa |
Green Published |
|
dc.description.pages |
11 |
|
dc.subject.kwp |
Care |
|
dc.subject.kwp |
Art |
|
dc.subject.kwp |
Retention |
|
dc.subject.kwp |
Infection |
|
dc.subject.kwp |
Cascade |
|
dc.subject.kwp |
Rna |
|
dc.description.affiliation |
Univ Calif Berkeley, Sch Publ Hlth, 101 Haviland Hall, Berkeley, CA 94110 USA |
|
dc.description.affiliation |
Univ Calif San Francisco, San Francisco, CA 94143 USA |
|
dc.description.affiliation |
Harvard TH Chan Sch Publ Hlth, Boston, MA USA |
|
dc.description.affiliation |
Infect Dis Res Collaborat, Kampala, Uganda |
|
dc.description.affiliation |
Kenya Govt Med Res Ctr, Nairobi, Kenya |
|
dc.description.affiliation |
Makerere Univ, Kampala, Uganda |
|
dc.description.email |
mayaliv@berkeley.edu |
|
dc.description.corr |
Petersen, M (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, 101 Haviland Hall, Berkeley, CA 94110 USA. |
|
dc.description.orcid |
Asiphas, Owaraganise/0000-0002-5594-0310 |
|